Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective Study

In patients with moderate-to-severe plaque psoriasis, biologic therapy has become a mainstay of treatment.Of recent agents, tildrakizumab is a monoclonal antibody targeting interleukin-23 (IL-23) that has been approved for treatment of moderate-to-severe plaque psoriasis in several countries worldwide [1].While phase III clinical trials and subsequent open-label extension studies have evaluated its efficacy and safety, realworld evidence involving patients from routine clinical practice is limited [1,2].While our group previously reported real-world drug survival outcomes of up to 3 years with tildrakizumab, this

Authors

Institutions

Publication Details

Journal
Dermatology and Therapy
Published
2026-01-23
DOI
https://doi.org/10.1007/s13555-026-01653-w
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective Study

Lara Valeska Maul, Eugenia Veronica Di Brizzi, F Prignano, Julia-Tatjana Maul et al.
Dermatology and Therapy
Psoriasis: Treatment and Pathogenesis
article

Real-World Effectiveness and Safety of Tildrakizumab for Plaque Psoriasis: A 3-Year International Multicenter Retrospective Study

Lara Valeska Maul, Eugenia Veronica Di Brizzi, F Prignano, Julia-Tatjana Maul, V Prajapati, Luca Potestio, P. Gisondi, Elena Del-Alcazar, Siddhartha Sood, Orhan Yilmaz, Anna López-Ferrer, M. Llamas-Velasco, JM Carrascosa, Stefano Piaserico, Asfandyar Mufti, Ronald B. Vender, Gianmarco Silvi, Carlo Giovanni Carrera, Jensen Yeung, Barbara Guerra Leal, Luis Puig, Angelo Valerio Marzano, Anna Balato, Francesco Bellinato, Tiago Torres
article en

Abstract

In patients with moderate-to-severe plaque psoriasis, biologic therapy has become a mainstay of treatment.Of recent agents, tildrakizumab is a monoclonal antibody targeting interleukin-23 (IL-23) that has been approved for treatment of moderate-to-severe plaque psoriasis in several countries worldwide [1].While phase III clinical trials and subsequent open-label extension studies have evaluated its efficacy and safety, realworld evidence involving patients from routine clinical practice is limited [1,2].While our group previously reported real-world drug survival outcomes of up to 3 years with tildrakizumab, this

Dermatology and TherapyVol. 16(2)
University of Verona (IT), Universitat Autònoma de Barcelona (ES), Sunnybrook Health Science Centre (CA), University of Padua (IT), University of Calgary (CA), Universidade do Porto (PT), University of Toronto (CA), University of Milan (IT), University of Campania "Luigi Vanvitelli" (IT), University of Zurich (CH), Hospital de Sant Pau (ES), Women's College Hospital (CA), Health Sciences Centre (CA), University Hospital of Basel (CH), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), University of Saskatchewan (CA), SKiN Health (CA), University Hospital of Zurich (CH), Probity Medical Research (CA), Hospital Universitario de La Princesa (ES), Dermatrials Research (CA), Hospital Universitari Germans Trias i Pujol (ES), Centro Hospitalar do Porto (PT), University of Florence (IT), University of Naples Federico II (IT), McMaster University (CA)
Partnerships for the goals
Openalex Percentile: Top 80%
Psoriasis: Treatment and Pathogenesis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.